[ad_1] UCB will contribute 14 presentations, including an oral presentation, selected to feature across the AANEM and MGFA meeting, emphasizing UCB’s leadership in neuromuscular research Presentations showcase new data for UCB’s gMG treatments, including post hoc […]
[ad_1] OSLO, Norway, Oct. 10, 2024 /PRNewswire/ — Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced that the first patient has been dosed in its Phase 2 study of […]
[ad_1] TOKYO, Oct. 10, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, will be […]
[ad_1] CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 9, 2024 /PRNewswire/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on […]
[ad_1] Implantable Neuromodulation System Shows Early Promise in Improving Patient Quality of Life by Reducing Monthly Headache Days and Severity of Migraine Attacks MINNEAPOLIS, Oct. 9, 2024 /PRNewswire/ — ShiraTronics, a clinical-stage medical device company […]
